

Wedbush PacGrow Life Sciences Releases Top Sector Trends for Investors Hosts Annual Institutional Management Access Conference

- *Conference expects more than 150 institutional investors with more than 70 public and private leaders in biotechnology, biopharmaceuticals, biodefense, emerging pharmaceuticals, healthcare services, managed care and medical diagnostics*
- *Wedbush analysts share life sciences trends, research, thought leadership*
- *Live webcasts available from select presenters including Celldex Therapeutics, Oncothyreon, and Puma Biotechnology*

New York, NY and Los Angeles, CA – August 14, 2012 – Wedbush Securities, one of the nation's leading broker dealers and [equity research firms](#), will host its annual [Wedbush PacGrow Life Sciences Management Access Conference](#) in New York from August 14 - 15, 2012. The conference connects leading Life Sciences organizations with Wedbush's institutional investing clients including financial advisory firms, hedge funds, and venture capitalists.

The event will address investment opportunities, and provide insight on trends and influences driving company performance through presentation tracks and small group meetings. A keynote presentation will be delivered by William Kitchens, a partner on the Food and Drug Practice Team at Arnall Golden Gregory, on the recently-signed FDA Safety and Innovation Act, including the changes to the accelerated approval process, generic drug development, medical device regulations, the FDA's Critical Path and Transparency Initiatives.

Ahead of the conference, Wedbush's Life Sciences Equity Research Analysts offer industry insight surrounding the **Top Life Sciences Trends** they feel investors should examine –

1. **Increasing investment in companies developing and selling orphan drugs to treat rare diseases –**
Historically, this segment was overlooked because the pharmaceutical industry could not afford to spend hundreds of millions of dollars to develop drugs for so few patients as they could not recover their costs. The government has since recognized this unmet need and provided incentives including more lenient drug development and approval hurdles. We believe this trend is likely to continue as healthcare budgets continue to shrink -- creating pricing pressure on non-orphan drugs.
2. **Following a year of record returns, managed care is heading towards a challenging 2013 / 2014, driving a flight to the highest quality insurers –** We anticipate margin compression in the commercial market in 2013 as the pricing cycle declines and utilization levels come back, supported by our proprietary consumer and physician surveys.

Companies scheduled to present include: Acceleron Pharma; Achillion Pharmaceuticals; Addex Therapeutics; Affymetrix; Amarin Corporation; Anacor Pharmaceuticals; Arrowhead Research; Avanir Pharmaceuticals; Biodel; BioDelivery Sciences International; BioMimetic Therapeutics; Cadence Pharmaceuticals; Cardica Inc.; CardioDx; Celldex Therapeutics; Cepheid; Cerus; Chelsea Therapeutics; Cleveland BioLabs; Concert Pharmaceuticals; Coronado

Biosciences; Cubist Pharmaceuticals; Curis; Cylene Pharmaceuticals; Delcath Systems; Durata Therapeutics; Emergent BioSolutions; Endocyte; Epizyme; Exact Sciences; Gentium S.p.A.; GTx, Inc.; HeartWare International; Idenix Pharmaceuticals; Ikaria; Immunomedics; IMRIS; Insmed; Ironwood Pharmaceuticals; Lexicon Pharmaceuticals; Medivation; NeurogesX; Novavax; NPS Pharmaceuticals; NuPathe; Omeros; Oncothyreon; Pacira Pharmaceuticals; Peregrine Pharmaceuticals; Pharmacyclis; Presidio Pharmaceuticals; PTC Therapeutics; Puma Biotechnology; Raptor Pharmaceutical; Receptos; Regado Biosciences; Sangamo BioSciences; Sarepta Therapeutics; Sequenom; Sunesis Pharmaceuticals; Synageva Biopharma; Synta Pharmaceuticals; Tactic Pharma; Uroplasty; Ultragenyx; Viamet Pharmaceuticals; XenoPort; Xoma and Zalicus.

The Wedbush PacGrow Life Sciences Management Access Conference is by invitation only, please contact Wedbush Securities for additional information.

###

About Wedbush Securities

Founded in 1955, Wedbush Securities is a leading investment firm that provides brokerage, clearing, investment banking, equity research, public finance, fixed income sales and trading, and asset management to individual, institutional and issuing clients. Headquartered in Los Angeles, with over 100 offices, the firm focuses on relentless service, client financial safety, continuity, and advanced technology. Wedbush Securities is the largest subsidiary of holding company [WEDBUSH, Inc.](#), which also includes affiliated firms [Wedbush Bank](#), [Wedbush Capital Partners](#), [Wedbush Opportunity Partners](#), and [Lime Brokerage LLC](#). Follow us on Twitter [@Wedbush](#).